| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Nuclear Medicine and Internal Medicine III, University Hospital Dijkzigt, Rotterdam, The Netherlands
Sandoz Research Institute, Berne and Department of Endocrinology, Sandoz Pharma AG, Basel, Switzerland
Correspondence: For reprints contact: E. P. Krenning, MD, PhD, Professor of Nuclear Medicine, University Hospital Dijkzigt, Department of Nuclear Medicine, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
ABSTRACT
Scintigraphy with 123I-Tyr-3-octreotide has several major drawbacks as regards its metabolic behavior, its cumbersome preparation and the short physical half-life of the radionuclide. The use of another radiolabeled analog of somatostatin, 111In-DTPA-D-Phe-1-octreotide, has consequently been proposed. DTPA-D-Phe-1-octreotide can be radiolabeled with 111In in an easy single-step procedure. DTPA-D-Phe-1-octreotide is cleared predominantly via the kidneys. Fecal excretion of radioactivity amounts to only a few percent of the administered radioactivity. For the radiation dose to normal tissues, the most important organs are the kidneys, the spleen, the urinary bladder, the liver and the remainder of the body. The calculated effective dose equivalent is 0.08 mSv/MBq. Optimal 111In-DTPA-D-Phe-1-octreotide scintigraphic imaging of various somatostatin receptor-positive tumors was obtained 24 hr after injection. In the six patients studied, tumor localization with 123I-Tyr-3-octreotide and with 111In-DTPA-D-Phe-1-octreotide were found to be similar. However, the normal pituitary is more frequently visualized with the latter radio-pharmaceutical. In conclusion, 111In-DTPA-D-Phe-1-octreotide appears to be a sensitive somatostatin receptor-positive tissue-seeking radiopharmaceutical with some remarkable advantages: easy preparation, general availability, appropriate half-life and absence of major interference in the upper abdominal region, because of its renal clearance. Therefore, 111In-DTPA-D-Phe-1-octreotide may be suitable for use in SPECT of the abdomen, which is important in the localization of small endocrine gastroenteropancreatic tumors.
This article has been cited by other articles:
|
|
 |
|
  D. K. Kontogeorgakos, P. A. Dimitriou, G. S. Limouris, and L. J. Vlahos Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery J. Nucl. Med., September 1, 2006; 47(9): 1476 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Meisetschlager, T. Poethko, A. Stahl, I. Wolf, K. Scheidhauer, M. Schottelius, M. Herz, H. J. Wester, and M. Schwaiger Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide J. Nucl. Med., April 1, 2006; 47(4): 566 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hofmann, K. C. Wollert, G. P. Meyer, A. Menke, L. Arseniev, B. Hertenstein, A. Ganser, W. H. Knapp, and H. Drexler Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium Circulation, May 3, 2005; 111(17): 2198 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miao, N. K. Owen, D. R. Fisher, T. J. Hoffman, and T. P. Quinn Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models J. Nucl. Med., January 1, 2005; 46(1): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nguyen, M. Faraggi, A.-L. Giraudet, C. de Labriolle-Vaylet, T. Aparicio, F. Rouzet, M. Mignon, S. Askienazy, and I. Sobhani Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy J. Nucl. Med., October 1, 2004; 45(10): 1660 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Rolleman, E. P. Krenning, A. van Gameren, B. F. Bernard, and M. de Jong Uptake of [111In-DTPA0]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose J. Nucl. Med., April 1, 2004; 45(4): 709 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lubberink, V. Tolmachev, C. Widstrom, A. Bruskin, H. Lundqvist, and J.-E. Westlin 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET J. Nucl. Med., October 1, 2002; 43(10): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Anderson, F. Dehdashti, P. D. Cutler, S. W. Schwarz, R. Laforest, L. A. Bass, J. S. Lewis, and D. W. McCarthy 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors J. Nucl. Med., February 1, 2001; 42(2): 213 - 221. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Lugtenburg, B. Löwenberg, R. Valkema, H.-Y. Oei, S. W. Lamberts, M. J. Eijkemans, W. L. van Putten, and E. P. Krenning Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas J. Nucl. Med., February 1, 2001; 42(2): 222 - 229. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Ferone, M. P. van Hagen, D. J. Kwekkeboom, P. M. van Koetsveld, D. M. Mooy, E. Lichtenauer-Kaligis, A. Schönbrunn, A. Colao, S. W. J. Lamberts, and L. J. Hofland Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in Vitro J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1719 - 1726. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Raderer, A. Kurtaran, M. Leimer, P. Angelberger, B. Niederle, H. Vierhapper, F. Vorbeck, M. H. L. Hejna, W. Scheithauer, J. Pidlich, et al. Value of Peptide Receptor Scintigraphy Using 123I-Vasoactive Intestinal Peptide and 111In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998 J. Clin. Oncol., March 13, 2000; 18(6): 1331 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lewis, M. R. Lewis, P. D. Cutler, A. Srinivasan, M. A. Schmidt, S. W. Schwarz, M. M. Morris, J. P. Miller, and C. J. Anderson Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model Clin. Cancer Res., November 1, 1999; 5(11): 3608 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Rogers, S. F. McLean, R. L. Kirkman, D. Della Manna, S. J. Bright, C. C. Olsen, A. D. Myracle, M. S. Mayo, D. T. Curiel, and D. J. Buchsbaum In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector Clin. Cancer Res., February 1, 1999; 5(2): 383 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Giblin, N. Wang, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn Design and characterization of alpha -melanotropin peptide analogs cyclized through rhenium and technetium metal coordination PNAS, October 27, 1998; 95(22): 12814 - 12818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Kouroumalis, P Skordilis, K Thermos, A Vasilaki, J Moschandrea, and O N Manousos Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study Gut, March 1, 1998; 42(3): 442 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wangberg, O. Nilsson, V. Johanson, L. Kolby, E. Forssell-Aronsson, P. Andersson, M. Fjalling, L.-E. Tisell, and H. Ahlman Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors Oncologist, February 1, 1997; 2(1): 50 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Virgolini, M. Raderer, A. Kurtaran, P. Angelberger, S. Banyai, Q. Yang, S. Li, M. Banyai, J. Pidlich, B. Niederle, et al. Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors N. Engl. J. Med., October 27, 1994; 331(17): 1116 - 1121. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
